Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Endogenous Metabolite
    (4)
  • PPAR
    (2)
  • AMPK
    (1)
  • Antibacterial
    (1)
  • Apoptosis
    (1)
  • COX
    (1)
  • Cannabinoid Receptor
    (1)
  • Casein Kinase
    (1)
  • Cytochromes P450
    (1)
  • Others
    (39)
Filter
Search Result
Results for "

glucose tolerance

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    64
    TargetMol | Inhibitors_Agonists
  • Compound Libraries
    1
    TargetMol | Compound_Libraries
  • Peptide Products
    2
    TargetMol | Peptide_Products
  • Inhibitory Antibodies
    1
    TargetMol | Inhibitory_Antibodies
  • Natural Products
    11
    TargetMol | Natural_Products
  • Recombinant Protein
    2
    TargetMol | Recombinant_Protein
  • Cell Research
    1
    TargetMol | Inhibitors_Agonists
CCG-1423
CCG1423
T2014285986-88-1
CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
AMPK activator 4
T622382493239-46-4In house
AMPK activator 4 is a potent and selective AMPK activator that does not inhibit mitochondrial complex I. It selectively activates AMPK in muscle tissue, dose-dependently improves glucose tolerance in normal mice, significantly reduces fasting glucose levels, and improves insulin resistance in db db diabetic mice. [AMPK activator 4 has hypoglycemic effects.]
  • Inquiry Price
6-8 weeks
Size
QTY
Phanginin A
T730741011528-58-7In house
Phanginin A, a potent and orally active activator of salt-induced kinase 1 (SIK1), effectively inhibits gluconeogenesis, increases the expression of p-SIK1, and decreases the expression of p-CREB. By reducing blood glucose levels and enhancing glucose tolerance and dyslipidemia, Phanginin A holds potential for type 2 diabetes research.
  • Inquiry Price
Size
QTY
trans-Cinnamic acid
trans-3-Phenylacrylic acid, Phenylacrylic acid, Isocinnamic acid, Cinnamylic acid, Cinnamic acid, 3-Phenylacrylic acid
T2740140-10-3
trans-Cinnamic acid (Myricitrine) exerts anti-diabetic activity by improving glucose tolerance in vivo and by stimulating insulin secretion in vitro.
  • Inquiry Price
Size
QTY
Oxfenicine
4-Hydroxy-L-phenylglycine
T478532462-30-9
Oxfenicine (4-Hydroxy-L-phenylglycine) is a carnitine palmitoyltransferase-1 inhibitor. Oxfenicine improves whole-body glucose tolerance and insulin sensitivity in high-fat diet-induced obese mouse with insulin resistance.
  • Inquiry Price
Size
QTY
HWL-088
T115832378617-96-8
HWL-088 is a potent free fatty acid receptor 1 (FFA1 GPR40) agonist. HWL-088 significantly improves glucose tolerance in normal and diabetic models.
  • Inquiry Price
6-8 weeks
Size
QTY
KPLH1130
T11765906669-07-6
KPLH1130, a specific pyruvate dehydrogenase kinase (PDK) inhibitor, enhances glucose tolerance in mice fed a high-fat diet (HFD). It effectively hinders macrophage polarization and mitigates proinflammatory reactions.
  • Inquiry Price
Size
QTY
PF-5006739
T165071293395-67-1
PF-5006739 is an effective and selective inhibitor of CK1δ ε (IC50s: 3.9 nM and 17.0 nM, respectively). PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ ε and high kinome selecti
  • Inquiry Price
7-10 days
Size
QTY
SX29
T200432
SX29 is a non-competitive α-glucosidase inhibitor with oral activity, exhibiting an IC50 of 2.12 μM. It possesses hypoglycemic properties; oral administration of SX29 reduces blood glucose levels and enhances glucose tolerance in diabetic mice.
  • Inquiry Price
Size
QTY
YH18968
YH-18968, YH 18968
T2029691632498-56-6
YH18968, a GPR119 agonist, improves glucose tolerance and enhances blood glucose-lowering effects. When combined with dipeptidyl peptidase-4 (DPP-4) inhibitors, YH18968 increases the plasma levels of active GLP-1 in normal mice.
  • Inquiry Price
Size
QTY
KOTX1
T2031911788963-83-6
KOTX1 is an orally active and selective inhibitor of ALDH1A3. In a diabetic mouse model, KOTX1 improves glucose tolerance, insulin secretion, and blood glucose levels.
  • Inquiry Price
Size
QTY
α-Glucosidase-IN-77
T203496
α-Glucosidase-IN-77 (Compound H7) is a non-competitive α-glucosidase inhibitor with an IC50 of 1.25 μM. It reduces blood glucose levels, improves glucose tolerance, regulates gut microbiota, and exhibits hepatoprotective effects in a mouse model of type 2 diabetes.
  • Inquiry Price
Size
QTY
PPARγ modulator-2
T2050682897652-01-4
PPARγmodulator-2 (Compound (R)-2n) is a reversible modulator of PPARγ, inhibiting the PPARγ ligand-binding domain (LBD) with an IC50 of 41 nM. It helps lower blood glucose levels, improves glucose tolerance and insulin sensitivity, and demonstrates antidiabetic activity in db db mouse models.
  • Inquiry Price
10-14 weeks
Size
QTY
Linogliride
McN-3935,McN3935,McN 3935,Linogliridum,Linoglirida
T2573975358-37-1
Linogliride is a guanidine-based inhibitor of insulin secretion and a structural analog of pirogliride with hypoglycemic activity. It blocks ATP-sensitive potassium channels in the pancreatic beta cell membrane, thereby stimulating insulin secretion and improving glucose tolerance.
  • Inquiry Price
6-8 weeks
Size
QTY
Linogliride fumarate
McN 3935,McN-3935,McN3935
T25739L78782-47-5
Linogliride fumarate is the fumarate salt of Linogliride. Linogliride is a guanidine-based inhibitor of insulin secretion and a structural analog of pirogliride with hypoglycemic activity. It blocks ATP-sensitive potassium channels in the pancreatic beta cell membrane, thereby stimulating insulin secretion and improving glucose tolerance.
  • Inquiry Price
6-8 weeks
Size
QTY
SIRT6-IN-1
T287841214468-35-5
SIRT6-IN-1, a novel SIRT6 inhibitor, reduces glycemia and improves oral glucose tolerance in unfed wild-type mice.
  • Inquiry Price
6-8 weeks
Size
QTY
WB403
WB-403,WB 403
T291541594041-84-5
WB403 is a TGR5 activator. WB403 significantly decreases fasting blood glucose, postprandial blood glucose and HbA1c, improves glucose tolerance in type 2 diabetic mice. WB403 increases pancreatic β-cells and restores the normal distribution pattern of α-
  • Inquiry Price
6-8 weeks
Size
QTY
ASP-8497
UNII-GC7THT248G,ASP8497,ASP 8497
T30169651055-26-4
ASP8497 is a potent, long-acting DPP-IV inhibitor that improves glucose tolerance by elevating GLP-1 levels in a glucose-dependent insulin-stimulating manner. The compound is used as a therapeutic agent for impaired glucose tolerance and type 2 diabetes.
  • Inquiry Price
8-10 weeks
Size
QTY
AM-2394
AM2394
T33121442684-77-6
AM-2394 is an effective and specific Glucokinase agonist (GKA, EC50: 60 nM), which catalyzes the phosphorylation of glucose to glucose-6-phosphate. AM-2394(AM2394) increases the affinity of GK for glucose by approximately 10-fold, exhibits moderate clearance and good oral bioavailability in multiple animal models, and lowers glucose excursion following an oral glucose tolerance test in an ob ob mouse model of diabetes.
  • Inquiry Price
Size
QTY
YW1128
T355472131223-64-6
YW1128 is an inhibitor of Wnt/β-catenin signaling with an IC50 value of 4.1 nM in a reporter assay.1 It decreases protein levels of β-catenin in the presence of the GSK3β inhibitor lithium chloride and increases protein levels of Axin1 in HEK293 cells. YW1128 decreases lipid accumulation and the expression of gluconeogenic and lipogenic genes in Huh7 cells. It decreases the hepatic expression of Wnt target genes, improves glucose tolerance, and prevents body weight increases and hepatic lipid accumulation in mice fed a high-fat diet, but not mice fed normal chow, when administered at a dose of 40 mg/kg every other day for 11 weeks.References1. Obianom, O.N., Ai, Y., Li, Y., et al. Triazole-based inhibitors of the Wnt/β-catenin signaling pathway improve glucose and lipid metabolism in diet-induced obese mice. J. Med. Chem. 62(2), 727-741 (2019). YW1128 is an inhibitor of Wnt/β-catenin signaling with an IC50 value of 4.1 nM in a reporter assay.1 It decreases protein levels of β-catenin in the presence of the GSK3β inhibitor lithium chloride and increases protein levels of Axin1 in HEK293 cells. YW1128 decreases lipid accumulation and the expression of gluconeogenic and lipogenic genes in Huh7 cells. It decreases the hepatic expression of Wnt target genes, improves glucose tolerance, and prevents body weight increases and hepatic lipid accumulation in mice fed a high-fat diet, but not mice fed normal chow, when administered at a dose of 40 mg/kg every other day for 11 weeks. References1. Obianom, O.N., Ai, Y., Li, Y., et al. Triazole-based inhibitors of the Wnt/β-catenin signaling pathway improve glucose and lipid metabolism in diet-induced obese mice. J. Med. Chem. 62(2), 727-741 (2019).
  • Inquiry Price
6-8 weeks
Size
QTY
FKGK 18
T356221071001-09-6
FKGK 18 is an inhibitor of group VIA (GVIA) calcium-independent phospholipase A2 (iPLA2). It inhibits GVIA iPLA2 by 99.9% at 0.091 mole fraction in a mixed micelle activity assay and is selective for GVIA iPLA2 over GIVA cPLA2 and GV sPLA2 where it shows 80.8 and 36.8% inhibition, respectively. FKGK 18 inhibits iPLA2β activity in cytosolic extracts from INS-1 cells overexpressing iPLA2β (IC50 = ~50 nM) as well as iPLA2γ activity in mouse heart membrane fractions (IC50s = ~1-3 μM). It inhibits glucose-induced increases in prostaglandin E2 production and insulin secretion in human pancreatic islets when used at a concentration of 10 μM and inhibits thapsigargin-induced apoptosis in INS-1 cells overexpressing iPLA2β in a concentration-dependent manner. FKGK 18 (20 mg/kg, 3 times per week) reduces blood glucose levels in an intraperitoneal glucose tolerance test, decreases the incidence of diabetes, and increases serum insulin levels in non-obese diabetic (NOD) mice.
  • Inquiry Price
6-8 weeks
Size
QTY
sr 1903
T356381414248-06-8
SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity.References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019). SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity. References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019).
  • Inquiry Price
6-8 weeks
Size
QTY
Massarigenin C
T35798496926-08-0
Massarigenin C is a fungal metabolite that has been found inM. flavoroseaand has enzyme inhibitory activities.1,2Massarigenin C inhibits neuraminidasein vitro(IC50= 4.15 μM).2It is also an inhibitor of yeast α-glucosidase (IC50= 1.25 mM).1It reduces the postprandial peak in blood glucose levels in an oral sucrose tolerance test in normo- and hyperglycemic mice when administered at doses of 3.2, 10, and 31.6 mg kg.
  • Inquiry Price
Size
QTY
ZLY032
T358162314465-67-1
ZLY032 is a dual agonist of free fatty acid receptor 1 (FFAR1/GPR40; EC50= 68 nM in a FLIPR assay) and peroxisome proliferator-activated receptor δ (PPARδ; EC50= 102 nM in a reporter assay).1It is selective for FFAR1 and PPARδ over PPARα and PPARγ (EC50s = >10 μM for both). ZLY032 (40 mg/kg, twice per day) reduces blood glucose levels in an oral glucose tolerance test and decreases plasma total cholesterol and triglyceride levels in theob/obmouse model of metabolic disease.2It reduces hepatic steatosis and plasma alanine transaminase (ALT) and aspartate aminotransferase (AST) levels in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a methionine and choline-deficient diet at the same dose. 1.Li, Z., Chen, Y., Zhou, Z., et al.Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agentsEur. J. Med. Chem.164352-365(2019) 2.Li, Z., Zhou, Z., Hu, L., et al.ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosisPharmacol Res.159105035(2020)
  • Inquiry Price
6-8 weeks
Size
QTY